Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory Choroidal Neovascularization (CNV) in Young Patients.

Trial Profile

Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory Choroidal Neovascularization (CNV) in Young Patients.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Choroidal neovascularisation
  • Focus Therapeutic Use
  • Acronyms ALINEA
  • Most Recent Events

    • 26 Jun 2017 Planned End Date changed from 1 Sep 2018 to 1 Sep 2020.
    • 26 Jun 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2020.
    • 21 Jun 2016 Planned End Date changed from 1 May 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top